Phase II clinical trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with previously untreated unresectable liver-only metastases from colorectal cancer
Ontology highlight
ABSTRACT: Primary objectives: To evaluate the response rate of patients with previously untreated unresectable liver-only metastases from colorectal cancer treated with neoadjuvant capecitabine and oxaliplatin plus bevacizumab.
Primary endpoints: Overall response rate according to RECIST criteria.
DISEASE(S): Metastatic Colorectal Adenocarcinoma With Metastases Involving The Liver Only,Colorectal Cancer Stage Iv
PROVIDER: 2518384 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA